United States Molecular Imaging Market Report by Modality, Application, End Use, States and Company Analysis, 2026-2034

United States Molecular Imaging Market Size and Forecast 2026-2034

United States Molecular Imaging Market is expected to reach US$ 3.6 Billion by 2034 from US$ 2.5 Billion in 2025, with a CAGR of 4.14% from 2026 to 2034. Rising cancer and cardiovascular disease prevalence, expanding theranostics, advances in PET and SPECT technologies, increasing radiopharmaceutical availability, AI-enabled image analysis, precision medicine adoption, and investments in advanced diagnostic infrastructure support market growth.

United States Molecular Imaging Industry Overview

The United States molecular imaging industry is developing rapidly as healthcare providers increasingly use imaging techniques that reveal biological, metabolic, and molecular processes rather than relying solely on anatomical information. The market includes positron emission tomography (PET), single-photon emission computed tomography (SPECT), PET/CT, SPECT/CT, molecular ultrasound, radiotracer-based imaging, and related software and image-analysis technologies. PET remains particularly important in oncology, neurology, and cardiology because radiotracers can identify disease activity and treatment response. SPECT continues to support cardiac, bone, and neurological examinations, while hybrid systems combine functional information with anatomical localization. Growing utilization of personalized medicine is also encouraging clinicians to use molecular imaging for disease characterization, patient selection, therapy monitoring, and treatment planning.

Technological innovation is strengthening the clinical and commercial potential of molecular imaging. Modern PET and SPECT systems increasingly emphasize higher sensitivity, faster acquisition, improved spatial resolution, quantitative imaging, and lower radiation exposure. Artificial intelligence and advanced software are also becoming important for reconstruction, segmentation, attenuation correction, image interpretation, and workflow optimization. In May 2026, GE HealthCare announced that its MIM KineticID dynamic-PET modeling software had reached the 510(k)-pending stage with the U.S. FDA, supporting quantitative assessment of tracer behavior over time. In September 2026, GE HealthCare also announced that StarGuide GX 4D SPECT/CT was 510(k) pending, incorporating CZT detector technology and capabilities designed for theranostics.

Cancer care represents one of the strongest applications because molecular imaging can identify tumors, evaluate biological characteristics, stage disease, assess treatment response, and increasingly support radioligand therapy selection. Neurological applications are also expanding, particularly for conditions involving abnormal protein accumulation and neurodegeneration. Cardiovascular imaging remains significant for myocardial perfusion and functional assessment. The growing integration of diagnostic imaging with theranostics is creating additional demand for specialized scanners and radiopharmaceuticals. Siemens Healthineers completed a US$43.6 million expansion at its Rockford, Tennessee PET detector facility in September 2026, adding 40,000 square feet to increase production capacity in response to demand associated with radiopharmaceutical-based cancer care, neurology, and cardiac imaging. Overall, increasing disease burden, technological progress, radiopharmaceutical innovation, and precision healthcare are supporting long-term expansion.

Growth Drivers for the United States Molecular Imaging Market

Expanding Role of Precision Oncology and Theranostics

The increasing emphasis on precision oncology is transforming molecular imaging from a diagnostic modality into an important component of treatment selection and therapeutic monitoring. PET and SPECT can visualize specific biological targets, helping physicians determine disease characteristics and identify patients potentially suitable for targeted radiopharmaceutical therapies. The expansion of theranostics is particularly important because the same molecular target can potentially be used for diagnostic imaging and therapeutic delivery. The FDA's July 2026 approval expanding lutetium Lu 177 vipivotide tetraxetan (Pluvicto) to combination therapy for certain PSMA-positive metastatic prostate cancer illustrates this direction; patient selection relies on PSMA PET imaging using Locametz or another approved PSMA PET product. As radioligand therapies expand, demand for molecular imaging equipment, radiotracers, quantitative software, and specialized nuclear medicine services is expected to increase.

Technological Progress in PET, SPECT, and Image Analytics

Continuous innovation in scanner hardware and imaging software is improving the clinical utility of molecular imaging. Advances include high-sensitivity detectors, digital technologies, CZT-based SPECT, faster acquisition, improved spatial resolution, dynamic imaging, automated reconstruction, and quantitative analysis. These developments can improve diagnostic confidence while supporting more efficient workflows and potentially reducing examination times. Dynamic PET is another emerging area because it evaluates how radiotracers move through tissues rather than simply producing a static image. GE HealthCare's MIM KineticID development demonstrates increasing emphasis on quantitative kinetic modeling and time-dependent tracer analysis. Meanwhile, StarGuide GX incorporates dual-sided CZT detector technology to address sensitivity and spatial-resolution requirements in advanced SPECT/CT applications. Such innovations encourage hospitals and imaging centers to upgrade aging equipment and broaden molecular imaging capabilities.

Rising Disease Burden and Increasing Advanced Diagnostic Utilization

The prevalence of cancer, cardiovascular disorders, and neurological diseases is creating sustained demand for sophisticated diagnostic technologies capable of identifying disease earlier and characterizing biological activity. Molecular imaging can contribute to cancer staging, recurrence assessment, treatment monitoring, cardiac perfusion evaluation, and neurological disease assessment. Its ability to provide functional information alongside anatomical imaging makes it valuable when conventional structural imaging does not fully capture disease activity. Demand is also supported by the growing use of personalized treatment strategies, where imaging information can influence therapy selection and monitor response. Siemens Healthineers highlighted increasing demand for PET detectors associated with cancer theranostics, Alzheimer’s disease evaluation, and cardiac imaging when announcing its Tennessee facility expansion. As healthcare systems increasingly emphasize earlier diagnosis, targeted treatment, and measurable therapeutic outcomes, molecular imaging is expected to gain importance across major clinical specialties.

Challenges in the United States Molecular Imaging Market

High Equipment, Infrastructure, and Operational Costs

Molecular imaging requires substantial capital investment because PET/CT and advanced SPECT/CT systems involve sophisticated detectors, scanners, computing infrastructure, shielding, specialized rooms, and maintenance requirements. Healthcare providers may also need dedicated nuclear medicine facilities and trained personnel to operate equipment and manage radiopharmaceutical workflows. Operational expenses can increase further because many radiotracers have specialized production, transportation, storage, and administration requirements. Smaller hospitals and independent diagnostic facilities can therefore face difficulties justifying investment in advanced systems when patient volumes are insufficient to support utilization. Equipment upgrades may also require substantial facility modifications, creating additional financial and operational burdens. Reimbursement variability can further influence purchasing decisions because providers must balance technology costs against achievable clinical volumes and payment levels. These factors can slow adoption in lower-volume facilities even as major academic hospitals, cancer centers, and large healthcare networks continue investing in advanced molecular imaging infrastructure.

Radiopharmaceutical Supply, Workforce, and Regulatory Complexity

Molecular imaging depends heavily on reliable access to radiopharmaceuticals, qualified nuclear medicine professionals, specialized technologists, physicists, radiochemists, and other trained personnel. Many radioactive compounds have short half-lives, making production, scheduling, transportation, and administration highly time-sensitive. Any disruption within the supply chain can affect examination availability and scanner utilization. The market also operates within complex regulatory requirements covering radioactive materials, medical devices, pharmaceuticals, manufacturing, transportation, radiation safety, and clinical use. Expanding theranostics introduces additional requirements because diagnostic imaging must be closely coordinated with therapeutic radiopharmaceutical workflows. Workforce shortages can create another constraint as advanced molecular imaging requires specialized knowledge in imaging protocols, radiotracer handling, quantitative interpretation, and radiation safety. Consequently, market expansion depends not only on installing scanners but also on strengthening radiopharmaceutical logistics, specialized training, regulatory capabilities, and multidisciplinary clinical infrastructure.

California Molecular Imaging Market - Innovation and Oncology Leadership

California represents one of the most technologically advanced molecular imaging markets in the United States, supported by major academic medical centers, cancer institutes, biotechnology companies, and sophisticated diagnostic networks. The state's large and diverse population creates substantial demand for PET/CT, SPECT/CT, and radiopharmaceutical-based diagnostic services. Molecular imaging is particularly relevant to oncology, where PET is increasingly integrated into staging, treatment planning, response assessment, and recurrence monitoring. California's strong biotechnology ecosystem also encourages collaboration between healthcare institutions, imaging companies, pharmaceutical developers, and radiopharmaceutical innovators. The state is additionally positioned to benefit from advances in artificial intelligence, quantitative imaging, and theranostics. Specialized centers are increasingly adopting advanced imaging capabilities to support precision medicine and clinical research. High healthcare expenditure and technology-oriented providers further support equipment modernization, although substantial capital requirements and uneven access between major metropolitan areas and rural communities remain important considerations for market development.

Texas Molecular Imaging Market - Expanding Healthcare Capacity

Texas has a large and rapidly developing healthcare ecosystem that supports strong demand for molecular imaging technologies. Major metropolitan areas including Houston, Dallas-Fort Worth, Austin, and San Antonio contain extensive hospital networks, cancer centers, research institutions, and diagnostic providers. Oncology is a particularly important application because PET-based imaging supports cancer detection, staging, treatment planning, and monitoring. Texas also benefits from significant research activity and specialized healthcare infrastructure, creating opportunities for adoption of advanced PET/CT and SPECT/CT systems. The Texas Cancer Registry continues to maintain detailed statewide cancer reporting infrastructure, including updated 2026 reporting guidance, supporting the broader importance of cancer diagnosis and surveillance within the healthcare system. Growing population, healthcare investment, and expansion of specialty care can encourage molecular imaging utilization. However, geographic differences in access to specialized imaging services and the cost of advanced equipment may influence adoption outside major urban centers.

New York Molecular Imaging Market - Advanced Clinical and Research Applications

New York represents a major molecular imaging market because of its concentration of hospitals, academic institutions, cancer centers, research organizations, and specialized diagnostic providers. New York City and surrounding metropolitan areas host sophisticated imaging infrastructure capable of supporting PET/CT, SPECT/CT, neurological imaging, cardiovascular studies, and radiopharmaceutical-based oncology services. The state's large patient population and high concentration of complex medical care support continued demand for advanced functional imaging. Molecular imaging is increasingly connected with precision oncology and theranostics, allowing clinicians to characterize molecular targets and evaluate treatment suitability. Academic and research institutions also contribute to clinical trials and technology development, encouraging the adoption of advanced quantitative imaging solutions. Investment in newer systems can improve diagnostic capabilities and workflow efficiency, while established healthcare networks can support radiopharmaceutical distribution and specialist staffing. Nevertheless, high facility costs, reimbursement considerations, and workforce requirements remain important factors affecting expansion across the state.

Florida Molecular Imaging Market - Aging Population and Specialty Care Demand

Florida offers strong potential for molecular imaging due to its large population, substantial healthcare infrastructure, and significant demand for services associated with aging-related diseases. The state's demographic profile supports applications across oncology, cardiology, neurology, and other specialties where functional and molecular information can improve diagnosis and treatment monitoring. Large metropolitan areas such as Miami, Orlando, Tampa, and Jacksonville contain hospitals, specialty centers, outpatient imaging facilities, and research organizations capable of supporting advanced PET and SPECT services. Cancer and cardiovascular care represent important utilization areas, while neurological imaging can benefit from growing interest in neurodegenerative disease assessment. Florida's extensive healthcare provider network also creates opportunities for diagnostic imaging centers to upgrade equipment and introduce higher-performance molecular imaging technologies. However, the availability of specialized personnel, radiopharmaceutical logistics, reimbursement conditions, and differences between metropolitan and less densely served areas can affect the pace of technology adoption.

Molecular Ultrasound - Functional Imaging Beyond Conventional Sonography

Molecular ultrasound imaging represents an emerging area within the broader molecular imaging landscape, using targeted contrast agents and ultrasound techniques to visualize specific biological processes. Unlike conventional ultrasound, which primarily provides anatomical and physiological information, molecular ultrasound aims to identify molecular targets associated with disease. The approach can potentially support applications in oncology, cardiovascular medicine, inflammation, vascular assessment, and targeted drug-delivery research. Its advantages include real-time imaging, comparatively low infrastructure requirements, portability, and the absence of ionizing radiation. Technological improvements in contrast-enhanced ultrasound, microbubble development, image processing, and targeted molecular probes are expanding research possibilities. In the United States, academic medical centers and biotechnology companies are contributing to the development of targeted ultrasound platforms and contrast agents. Commercial adoption remains more limited than PET or SPECT because molecular ultrasound is still developing clinically and requires further validation, regulatory progress, and standardized applications before achieving broader routine use.

Cardiovascular Imaging - Functional Assessment of Heart Disease

The cardiovascular application segment remains an important component of the United States molecular imaging market because molecular and nuclear imaging provide functional information that complements structural cardiac examinations. SPECT myocardial perfusion imaging has historically played an important role in evaluating blood flow and identifying ischemia, while PET offers quantitative assessment of myocardial perfusion and metabolic activity. Molecular imaging can support diagnosis, risk assessment, treatment planning, and evaluation of cardiac function in selected patient populations. Increasing cardiovascular disease burden and demand for non-invasive diagnostic approaches continue to support utilization. Technological improvements in detector sensitivity, quantitative reconstruction, hybrid PET/CT and SPECT/CT, and faster acquisition can further strengthen clinical efficiency. Siemens Healthineers specifically identified cardiac imaging as one factor contributing to demand for PET detector technology in its 2026 Tennessee manufacturing expansion. Future growth will also depend on reimbursement, radiotracer availability, specialist expertise, and integration with broader cardiovascular diagnostic pathways.

Diagnostic Imaging Centers - Expanding Outpatient Molecular Imaging Access

Diagnostic imaging centers are becoming increasingly relevant to molecular imaging as healthcare delivery gradually expands beyond traditional hospital-based settings. Independent and network-affiliated centers can provide PET/CT, SPECT/CT, and other advanced imaging services closer to patients, potentially improving convenience and reducing pressure on hospital imaging departments. Outpatient facilities increasingly emphasize efficient scheduling, high equipment utilization, digital image distribution, and specialized clinical services. Molecular imaging centers serving oncology, cardiology, and neurology patients can benefit from partnerships with hospitals, oncologists, radiologists, and radiopharmaceutical providers. The adoption of newer scanners and software can improve image quality, quantitative capabilities, workflow efficiency, and patient throughput. However, establishing molecular imaging capabilities requires significant investment in equipment, facility design, radiation protection, regulatory compliance, trained technologists, and radiopharmaceutical logistics. Consequently, larger imaging networks and high-volume centers are generally better positioned to adopt sophisticated molecular imaging systems than small independent facilities.

Market Segmentations

Modalitys

• Single Photon Emission Computed Tomography
• Psitron Emmission Tomography
• Nuclear Magnetic Resonance Spectrometer
• Molecular Utrasound Imaging
• Others

Application

• Oncology
• Cardiovascular
• Neurology
• Respiratory
• Gastrointestinal

End Use

• Hospitals
• Diagnostic Imaging Centers
• Research Institutes

Top States

• California
• Texas
• New York
• Florida
• Illinois
• Pennsylvania
• Ohio
• Georgia
• New Jersey
• Washington
• North Carolina
• Massachusetts
• Virginia
• Michigan
• Maryland
• Colorado
• Tennessee
• Indiana
• Arizona
• Minnesota
• Wisconsin
• Missouri
• Connecticut
• South Carolina
• Oregon
• Louisiana
• Alabama
• Kentucky
• Rest of United States

All Key Players have been covered with 5 Viewpoints

• Overviews
• Key Person
• Recent Developments
• SWOT Analysis
• Revenue Analysis

Key Players Analysis

1. GE HealthCare
2. Siemens Healthineers AG
3. Koninklijke Philips N.V.
4. Shimadzu Corp
5. United Imaging Healthcare Co., Ltd.
6. Bruker Corp
7. FUJIFILM Holdings Corp
8. Cubresa Inc.

Report Details: